The first new treatment for Alzheimer’s disease for nearly 20 years has been approved by regulators in the United States, paving the way for its use in the UK. Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms. Charities have welcomed the news of a new therapy.

Healthcare resources are more scarce than ever. The new normal has EMS as the “healthcare safety net” for most of the United States. Local EMS agencies, City EMS, are finding it more difficult to recruit qualified applicants. Moreover, they are finding it harder to find suitable personnel to apply and be trained. Many rural EMS.